Dermatology Times, March 2019 (Vol. 40, No. 3)

RT002 performs well in late-phase study

March 27, 2019

Revance Therapeutics announced in early December that its longacting neuromodulator daxibotulinumtoxinA for Injection RT002 delivered positive results in a phase 3 study for treatment of moderate-to-severe glabellar lines.

Nature-based skin care effective as adjunct to prescription rosacea therapy

March 27, 2019

Burt's Bees skin care products may be a effective as an adjunct to prescription therapy in the management of rosacea, according to data published in the February issue of Journal of Drugs in Dermatology which was reported at the American Academy of Dermatology Annual Meeting this month.

Dermatology department renamed to recognize Dr. Phillip Frost

March 27, 2019

The University of Miami Dermatology department has received a $10 million endowment from alumnus and philanthropist, Phillip Frost, M.D., and wife, Patricia. The gift will support the advancement of innovative treatments in dermatology within the newly renamed Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery.

Dermoscopy: The dermatologist’s stethoscope

March 27, 2019

There have been major technological advances in optical imaging techniques over the last decade, but the dermatoscope remains the diagnostic tool of choice for the quick and accurate imaging of pigmented skin lesions. Find out why in this article.

Sustaining a socioeconomically inclusive dermatology practice

March 26, 2019

Most dermatologists train in a clinical setting that accepts underinsured patients, but only some physicians continue along this path. Elaine Siegfried, M.D. offers her point of view on the pros and cons of working with this population, and discusses how to maintain a socioeconomically inclusive dermatology practice.

Novel dermatology drugs approved in 2018

March 22, 2019

In many ways, 2018 was a banner year for new novel drug approvals with 59 drugs approved by the FDA’s Center for Drug Evaluation and Research (CDER). Learn about the innovative drugs that were approved for dermatological indications in this article. 

Future of skin resurfacing lies in drug delivery, postprocedural care

March 06, 2019

Fractional ablative and nonablative lasers cover a wide variety of indications, but skin tightening results often require adjunctive treatment modalities and postprocedural regimens remain a puzzle, says Susan Van Dyke, M.D.

Can-Fite explores muscle tissue to fight psoriasis, cancer

March 06, 2019

Chief executive officer of Can-Fite Biopharmaceuticals, Pnina Fishman, Ph.D. discovered why cancer and inflammation can go everywhere in the body, except muscle tissue. Using this knowledge, Can-Fite has developed a promising psoriasis drug, piclidenoson, which is currently in phase 3 clinical trials.

A look at the life cycle of drugs in dermatology

March 03, 2019

To help providers have a greater understanding of the efforts of the FDA to ensure all drugs are of pharmaceutical quality, Michael Kopcha, Ph.D., RPh, director of the FDA’s Office of Pharmaceutical Quality presented on the topic during the American Academy of Dermatology’s Annual Meeting in Washington, D.C.

Medical device regulation impacts patient care

March 02, 2019

Laura Marquart, M.D., FAAD, medical officer with the FDA’s Center for Devices and Radiological Health (CDRH), reviewed how the FDA approaches, reviews, and approves medical devices integral to dermatologic care at the American Academy of Dermatology’s annual meeting in Washington, D.C. Learn how this process can affect patient care in this article.

Targeted therapy for skin malignancies

January 22, 2019

The past decade has seen significant advances in the understanding of molecular pathogenesis of skin cancer leading to the development of targeted treatments and immunotherapies that have dramatically improved progression free survival and even overall survival in melanoma, basal cell carcinoma (BCC) and even some rarer cutaneous carcinomas.

Possible tool to quickly assess BRAF, NRAS status

January 16, 2019

Cell-free circulating DNA (cfDNA) can provide a useful snapshot of the BRAF and NRAS genotype of melanoma patients’ tumor tissue and act as a useful surrogate to assessing tissue biopsies for the markers, a recent study suggests.

Cosmetic procedures more than vanity

November 20, 2018

Rather than being fueled by a singular desire to be more physically attractive, patients seeking cosmetic procedures are driven by emotional, physical, social and professional reasons, a JAMA Dermatology study shows.